Objective: To evaluate the effect of thymol administration on the serum concentration of
netrin-1 in obese subjects.
Material and methods: this is a randomized, double-blind, placebo-controlled clinical trial
design.
Inclusion criteria:
1. - Subjects between 18 and 35 years old.
2. - Subjects with BMI ≥ 30.0 and ≤35.0.
3. - Subjects with systolic blood pressure less than 135 mmHg.
4. - Subjects with diastolic blood pressure less than 85 mmHg.
5. - Voluntary acceptance and signing of the informed consent. These patients will be
randomly assigned to two groups, one will have the intervention with thymol 200 mg every
8 hours for 90 days while the other will have placebo with Mg 200 mg every 8 hours for
90 days.
Statistical analysis: quantitative variables: means and standard deviation. Qualitative
variables: frequencies and percentages. In the comparison according to the serum level of
netrin-1 between the two groups after the intervention: t student for quantitative variables,
Chi square for qualitative variables. Statistical significance p equal to or less than 0.05.
Centro Universitario de Ciencias de la Salud, Mexico
30Patients around the world
Requirements for the patient
To 35 Years
All Gender
Medical requirements
Subjects between 18 and 35 years old.
BMI ≥ 30.0 and ≤35.0
Systolic blood pressure less than 135 mmHg.
Diastolic blood pressure less than 85 mmHg.
Subjects who are known to have a diagnosis, receive treatment, or are observed with:
- Rheumatological and / or thyroid disease.
- Chronic kidney disease and / or CKD-EPI glomerular filtration rate less than 60 ml / min / 1.72m2.
- Innate alterations of metabolism.
- Elevation of transaminases 2 times higher than normal.
- Total cholesterol greater than 250 mg / dl.
- Triglycerides greater than 300 mg / dl.
Subjects presenting with acute illness, hospitalization, or drug treatment presented in the last 12 weeks prior to the study selection visit.
Subjects with symptoms consistent with the definition of a probable case of COVID-19, as well as any subject with a diagnosis of COVID-19.
Subjects who have had blood transfusions in the last 3 months.
Regular smokers.
Pregnant or lactating women.
Women with a desire for pregnancy or who do not have a double barrier or progestin-only contraceptive method.
SponsorCentro Universitario de Ciencias de la Salud, Mexico